Wednesday 17th September - Main Conference Day Two - ET (Eastern Time, GMT-05:00)
- How to effectively adopt AI tools in the CGT space
- Opportunities for AI and machine learning in process development & manufacturing
- Real-world applications of AI in CGT pipeline development
- Case study insights on AI-driven innovation
Delivery of plasmid DNA enables systemic expression of therapeutic molecules, including but not limited to monoclonal antibodies, proteins and peptides. However conventional delivery techniques are limited by constraints of redosability and toxicity in their ability to delivery DNA effectively. Polymeric systems can overcome these constraints but have a very large design space. This presentation will describe how machine learning can leverage large design spaces for the design of polymeric delivery vehicles for a broad range of therapeutically relevant molecules in vivo.
- Shashi Murthy, PhD - CTO and Co-Founder, Nanite Inc.
- Pauline Schmit - Senior Scientist, nChroma Bio
- Kristy Wood, PhD - SVP, Technical Operations, Intellia Therapeutics
- Devyn M. Smith - Chief Executive Officer, Arbor Biotechnologies
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- Ratnesh Joshi - Associate Director, Downstream Process Development, Editas Medicine
- Weiyi Li - Senior Manager, LNP Formulation, Prime Medicine, Inc.
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: Partners@informaconnectls.com
- Internalising or externalising manufacturing – What are the decision points?
- How to select CDMO partners? – Industry criteria for selection
- When / what stage of development should you bring on second CDMO?
- Understanding CDMO capacities, timelines, and capabilities
- Qualification, and quality agreements for commercial manufacturing
- Tech transfer: best practices and risk management
- Strategies for transferring product from development phase to CDMO for large scale production: How to scale up?
- Lessons learnt from transferring to CDMO and vice versa
- Increasing skills and experience in manufacturing of next generation CGT products
- Partnership and communication – how to partner most effectively with CDMOs?
- Shankar Swaminathan, PhD - Team Lead, Associate Director Drug Product Development, Astellas Institute for Regenerative Medicine
- Jeff Masten - Senior Vice President CMC, Secretome Therapeutics
- Matthew Provencal - Executive Director Gene Therapy BDS Manufacturing, Sarepta